Castle Biosciences
CSTL
146 hedge funds and large institutions have $491M invested in Castle Biosciences in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 72 increasing their positions, 29 reducing their positions, and 36 closing their positions.
148% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 29
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
3.85% less ownership
Funds ownership: 89.76% → 85.91% (-3.9%)
9% less funds holding
Funds holding: 160 → 146 (-14)
31% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 36
50% less capital invested
Capital invested by funds: $988M → $491M (-$498M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$14.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$10.3M |
| 3 |
GF
Greenhouse Funds
Baltimore,
Maryland
|
+$10.2M |
| 4 |
RI
RTW Investments
New York
|
+$9.69M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$7.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$28M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$27.2M |
| 3 |
GPGA
Grandeur Peak Global Advisors
Salt Lake City,
Utah
|
-$24.4M |
| 4 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$24.2M |
| 5 |
PM
Pembroke Management
Montreal,
Quebec, Canada
|
-$20.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GWS
176
Glassman Wealth Services
Vienna,
Virginia
| – | -$1K | -23 | Closed |
|
|
CA
177
Clearstead Advisors
Cleveland,
Ohio
| – | -$1K | -22 | Closed |
|
178
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$1K | -20 | Closed |
|
|
AAP
179
Arax Advisory Partners
Denver,
Colorado
| – | -$1K | -12 | Closed |
|
|
CAL
180
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | -$23 | -1 | -13% |
|
|
AF
181
Allworth Financial
Folsom,
California
| – | +$186 | +8 | New |
|
CSTL Hedge Fund Activity: Q2 2022 in Review
146 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q2 2022, worth a combined $491M — down 50% from $988M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of CSTL and 25 opened new positions — a net loss of 11 holders — while 29 trimmed existing stakes and 72 added.
The largest buyer was Millennium Management, adding an estimated $14.6M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $28M sold.
- 146 institutional investors held Castle Biosciences (CSTL) as of Q2 2022, down from 160 in Q1 2022.
- Funds reported $491M of Castle Biosciences stock for Q2 2022, down 50% quarter-over-quarter.
- 25 funds opened new Castle Biosciences positions in Q2 2022 and 36 closed out, a net change of -11 holders.
- The largest Castle Biosciences buyer in Q2 2022 was Millennium Management, an estimated $14.6M added.
- The largest Castle Biosciences seller in Q2 2022 was Point72 Asset Management, an estimated $28M sold.
Based on aggregated 13F filings for Q2 2022.